Abstract The survival of cardiomyocytes must be ensured as the myocardium adjusts to a myriad of competing physiological and pathophysiological demands. A significant loss of these contractile cells, together with their replacement by stiff fibrillar collagen in the form of fibrous tissue accounts for a transition from a usually efficient muscular pump into one that is failing. Cellular and subcellular mechanisms involved in the pathogenic origins of cardiomyocyte cell death have long been of interest. This includes programmed molecular pathways to either necrosis or apoptosis, which are initiated from ischemic or nonischemic origins. Herein, we focus on the central role played by a mitochondriocentric signaltransducer-effector pathway to nonischemic cardiomyocyte necrosis, which is common to acute and chronic stressor states. We begin by building upon the hypothesis advanced by Albrecht Fleckenstein and coworkers some 40 years ago based on the importance of calcitropic hormone-mediated intracellular Ca 2+ overloading, which predominantly involves subsarcolemmal mitochondria and is the signal to pathway activation. Other pathway components, which came to be recognized in subsequent years, include the induction of oxidative stress and opening of the mitochondrial inner membrane permeability transition pore. The ensuing loss of cardiomyocytes and consequent replacement fibrosis, or scarring, represents a disease of adaptation and a classic example of when homeostasis begets dyshomeostasis.
Introduction
The heart has classically been viewed as a postmitotic organ: Its parenchyma, composed of terminally differentiated highly specialized cardiomyocytes, is unable to replicate. In essence, the myocardium has a fixed number of cardiomyocytes. This perspective, however, has more recently been challenged. For example, Hosoda and coworkers [30] and Angert et al. [3] have given evidence of cell cycle activation and documented nuclear and cellular division of a subpopulation of cardiomyocytes. They would argue such endogenous progenitor cells exist and could be mobilized to regenerate myocardium following injury [3, 30] . Sanganalmath et al. [66] have focused on the mobilization of progenitor cells derived from bone marrow and their homing to the site of myocardial injury, where they would transdifferentiate and replace lost cardiomyocytes. One remains hopeful that in the future, such pluripotent cells, irrespective of their origin, could be strategically mobilized to rescue and rebuild injured myocardium.
These provocative possibilities notwithstanding, the survival of cardiomyocytes must be ensured as this muscular pump adapts to diverse physiological and pathophysiological stimuli. These include the following: the hemodynamic burden imposed by short-term pressure or volume loading, which respectively accompanies the physiological stress of isometric and isotonic exercise; the provocation incurred during elevations in circulating catecholamines associated with acute bodily injury; and the cumulative and persistent hemodynamic overloading and neurohormonal activation, which are integral to chronic stressor states, such as congestive heart failure. Its pumping efficiency is compromised when the cumulative loss of cardiomyocytes crosses the biological threshold and their replacement by stiff fibrillar collagen in the form of fibrous tissue poses an impediment to both the stretching and contraction of the myocardium while the hypertrophy of remaining muscle cells reaches its physiological limits. Such pathological remodeling accounts for the clinical transition to heart failure and holds true irrespective of the etiologic origins of cell loss or whether necrotic or apoptotic cell death pathways, or both, are involved. A critical loss of cardiomyocytes and the appearance of fibrosis are fundamental structural abnormalities accounting for the appearance of a failing muscular pump, while an ongoing loss of cardiomyocytes contributes to the progressive nature of heart failure (HF) [9, 18] .
The cellular and subcellular mechanisms involved in the pathogenic origins of cardiomyocyte cell death have long been of interest, be they related to reduced coronary blood flow with myocardial infarction, ischemia/reperfusion injury, or nonischemic necrosis. In a series of studies, many appearing in Pflügers Archives 40 years ago [20, 44, 83] , Fleckenstein and coworkers drew attention to the importance of excessive intracellular Ca 2+ accumulation (EICA) and the role of Ca 2+ overloaded mitochondria in particular, together with ATP depletion, in leading to nonischemic cardiomyocyte necrosis. Herein, we build upon their hypothesis and the central role played by a mitochondriocentric signal-transducer-effector pathway in accounting for necrotic cell loss and which is common to both acute and chronic stressor states. In so doing, we draw attention to mitochondria-targeted interventions and their potential as cardioprotective strategies in salvaging myocardium. For the reader interested in cardiomyocyte apoptosis, several reviews are recommended [28, 47, 77] .
The death of cardiomyocytes: necrosis and apoptosis
The death of cardiomyocytes involves complex programmed molecular pathways: one is termed necrosis [48] ; the other is termed apoptosis [28, 47, 77] . The potential contribution of another yet-to-be-fully elucidated pathway, termed autophagy with lysosomal-mediated autocannibalism, is in evolution, and its biological significance in the failing heart remains to be fully established [4, 12, 46, 58] .
Necrosis
Necrotic cell death is viewed as "dirty" death because the hyperpermeable cell on its terminal trajectory spills intracellular contents (e.g., troponins), which serve as "danger" signals to the innate immune system [54] . The ensuing invasion of inflammatory cells to the site of necrosis, together with recruited myofibroblasts, results in tissue repair and a subsequent reparative fibrosis. This myocardial scarring is a morphological footprint of previous necrosis, while elevated serum troponin levels represent molecular markers of recent cardiomyocyte necrosis.
Foci of fibrosis are found scattered throughout the myocardium of the right and left heart in the explanted failing human heart, where fibrosis is considered the major component to the adverse structural remodeling of myocardium [6] . It follows pari passu that necrosis is a major form of cardiomyocyte loss in the failing heart. The diffuse patchy distribution to myocardial scarring, often most prevalent in the endomyocardium, suggests that cardiomyocyte necrosis is widespread and likely to be an ongoing process. Each episode of necrosis and tissue repair is coupled to myofibroblast-derived collagen fibrillogenesis and the accumulation of stiff type I collagen [89] . This fibrillar collagen, which predominates in scar tissue, has the tensile strength equivalent to steel. In time, the progressive fibrosis of myocardium contributes to diastolic and systolic ventricular dysfunction [9, 18, 90] .
Apoptosis
Apoptosis, on the other hand, is considered a "sterile" form of cell death with cardiomyocytes rapidly engulfed by macrophages never to spill their contents nor to provoke the immune system or to invoke the invasion of inflammatory cells to the site of injury. Hence, tissue repair eventuating in fibrous tissue does not take place after apoptotic cell death. Accordingly, the apoptotic loss of cardiomyocytes leaves neither a morphological trail nor a biochemical footprint. Some would question the pathophysiological role of apoptosis in the loss of cardiomyocytes and the progression to HF [31, 69, 80, 81] . The Fleckenstein hypothesis of nonischemic cardiomyocyte necrosis has recently been broadened into a central mitochondriocentric signal transducer-effector (MSTE) pathway and found to be common to both acute and chronic stressor states [41, 74] . As Fleckenstein envisaged, the signal for this pathway includes catecholamine-or PTHmediated intracellular Ca 2+ overloading (see Fig. 1 . A more terminal event and pathway effector is a cyclophilin D-dependent opening of the mitochondrial inner membrane permeability transition pore (mPTP) [34] . The consequent osmotic-based entry of solutes and ongoing swelling accounts for the degeneration of these organelles, loss of ATP synthesis, and ensuing cardiomyocyte necrosis.
How cardiomyocytes determine the activation of apoptotic or necrotic cell death pathways is not fully understood and is under investigation [34, 56, 60] . The functional roles of these specific pathway components was selectively validated (vide infra) in acute and chronic stressor states using pharmacological agents that interrupted the cascade at specific downstream targets in rats receiving either Isop or 4-week aldosterone/salt treatment (ALDOST), respectively [38, 39, 73, 74] . We hypothesize that a lesser level of pathway activation, without ATP depletion, may lead to apoptosis, whereas a more severe activation and ATP depletion would result in irreparable damage with cardiomyocyte necrosis and reparative fibrosis in the heart as observed in our animal studies.
Acute stressor states
Following a single subcutaneous dose of Isop, ionized hypocalcemia is evident within 2 h and attributable to the translocation of Ca 2+ to diverse tissues that includes the heart, skeletal muscle, and peripheral blood mononuclear cells [74] . In cardiomyocytes, this EICA includes increased mitochondrial [Ca 2+ ] m coupled with increased H 2 O 2 production and increased plasma and cardiac tissue 8-isoprostane, a biomarker of lipid peroxidation, and enhanced propensity to mPTP opening, as evidenced by the response to experimental CaCl 2 stimulation. Intracellular Ca 2+ overloading and consequent necrosis with myocardial scarring that accompanies Isop-mediated hyperadrenergic state favors the endomyocardium of the left ventricular apex [7, 59, 64, 74, 88] . We believe this propensity to catecholamine-induced injury at the apex is in keeping with its greater β 1 -adrenergic receptor density [7, 14, 74] and that is driven by the apical to basal activation of the myocardium needed for the sequential peristaltic-like emptying of the ventricle into the aorta [10, 65, 70] . These pathophysiological events were abrogated by pretreatment with either carvedilol, a β-adrenergic receptor antagonist, or quercetin, a flavonoid, each of which have mitochondriatargeted antioxidant properties [42, 67, 72, 74, 84] . In ] m , specifically the subsarcolemmal (SSM) population of these organelles. In response to mitochondrial Ca 2+ overloading and ATP depletion, there follows the induction of oxidative stress by these organelles and subsequent opening of their inner membrane permeability transition pore (mPTP) with solute entry, osmotic swelling, and structural degeneration of these organelles. This programmed sequence of events leads to cardiomyocyte necrosis with a leakage of intracellular contents, including troponins. Tissue repair follows the loss of necrotic cardiomyocytes. This healing eventuates in a reparative fibrosis that preserves the structural integrity of the myocardium. Microscopic scarring represents a morphologic trail, with elevated serum troponins, the biochemical footprints of cardiomyocyte necrosis transgenic mice with enhanced sarcolemmal L-type Ca 2+ channel activity, a progressive necrosis of cardiomyocytes is seen together with consequent appearance of reparative fibrosis and pump dysfunction, which are accentuated by provocation with Isop [5] . In other rodent models, the loss of cyclophilin D blocked Ca 2+ overloading-based cardiomyocyte necrosis, while overexpression of Bcl-2, an antiapoptotic factor, proved ineffective [57] . Collectively, these findings support the central role of the MSTE pathway in nonischemic cardiomyocyte necrosis during acute hyperadrenergic states.
Chronic stressor states
Chronic inappropriate (relative to dietary Na + ) aldosteronism appears with congestive heart failure (CHF), low-renin hypertension, or the adrenal glands' autonomous production of aldosterone. ALDOST has been used in rats to induce a chronic stressor state to interrogate the specific MSTE pathway components. However, we have been unable to reproduce the expected cardiac remodeling in mice receiving ALDOST. Hence, we have not pursued genetic manipulations to further elucidate the pathway components in mice.
Chronic ALDOST in rats is associated with marked increments in fecal and urinary Ca 2+ excretion and that are already evident at week 1. For the fixed Ca 2+ intake attendant with laboratory chow provided to these rats, these excretory losses quickly lead to the appearance of plasma ionized hypocalcemia at week 1 generating a major stimulus to the parathyroid glands' increased secretion of PTH. The accompanying secondary hyperparathyroidism (SHPT) is further evidenced by bone resorption and a marked fall in bone mineral density and strength seen at weeks 4-6 ALDOST [ This prooxidant state is counterbalanced by an increment in antioxidant defenses, which also appears at week 1. This includes the increased activities of Cu/Zn superoxide dismutase and glutathione peroxidase and total antioxidant capacity, which consists of nonenzymatic low molecular weight antioxidants [38] . However, the persistent Ca 2+ overloading of cardiomyocytes present over 4 weeks leads to a dysequilibrium between pro-and antioxidants and altered redox state. In the absence of additional increments in endogenous defenses, a marked rise in reactive oxygen species generation by these organelles follows coupled with the subsequent opening of their inner membrane mPTP, leading to cardiomyocyte necrosis and consequent tissue repair. Cardiac pathology with microscopic scarring is first evident at 4-week ALDOST [41, 79] .
The crucial importance of PTH-mediated Ca 2+ overloadinginduced oxidative stress in leading to the proinflammatory cardiac failure phenotype of this model is evidenced by the upregulation of the redox-sensitive nuclear transcription factor (NF)-κB and the proinflammatory gene cascade it regulates, including ICAM-1, MCP 1 , and tumor necrosis factor alpha, and which are abrogated by cotreatment with an antioxidant N-acetylcysteine [79] . The importance of NF-κB signaling in the heart and its role as a signaling integrator has led some to propose targeting this mediator of cytokine responses in preventing pathological remodeling with HF [26, 37] .
The crucial importance of SHPT in mediating this pathophysiological scenario was demonstrated by a number of interventions. They included the following: cotreatment with spironolactone, an aldosterone receptor antagonist, which attenuated the marked excretory losses of Ca 2+ in feces and urine, and thereby prevented ionized hypocalcemia with SHPT [15]; cotreatment with a Ca 2+ and vitamin D 3 -supplemented diet to prevent ionized hypocalcemia and SHPT [25] ; surgical parathyroidectomy performed prior to initiating ALDOST [87] ; medical parathyroidectomy using cotreatment with a calcimimetic to raise the threshold of the Ca 2+ -sensing receptor of the parathyroids and prevent SHPT [71] ; and cotreatment with a Ca 2+ channel blocker [1] . In subsequent studies, the MSTE pathway components were addressed using mitochondria-targeted interventions (see Fig. 2 ). They included quercetin and cyclosporine A, an mPTP opening inhibitor. We found the marked increments in [Ca 2+ ] m and mitochondrial H 2 O 2 production, together with increased 8-isoprostane and propensity to their mPTP opening and myocardial scarring seen at week 4 ALDOST, were each attenuated by cotreatment with either of these agents. Mitochondrial electron transport as a source of reactive oxygen species has also been targeted for cardioprotection [85] , while in the vasculature, NADPH oxidase as a source of oxygen radical generation has been targeted [49, 61] . Table 1 ). In an effort to raise antioxidant defenses, cotreatment with a ZnSO 4 supplement was used. It raised cardiomyocyte [Zn 2+ ] i to 2.0 nM, which was significantly greater than that seen with ALDOST alone (see Table 1 ] i activate its sensor, MTF-1, which upon its translocation to the nucleus induces the transcription of antioxidant defense genes, including Cu/Zn superoxide dismutase, glutathione synthase and MT-1. Nebivolol and carvedilol are unique β 1 adrenergic receptor blockers in that they are also β 3 agonists that upregulates nitric oxide (NO) production from endothelial nitric oxide synthase (eNOS). In turn, NO releases Zn 2+ bound to MT-1, which promotes antioxidant defenses while it reduces LTCC-based Ca 2+ entry via upregulated cGMP. ROS reactive oxygen species, GC guanyl cyclase. Adapted with permission from [13] turn releases Zn 2+ , which had been inactive being bound to MT-1 (see Fig. 3 ] m levels were each reduced. By enhancing endogenous antioxidant capacity and reducing EICA, the multifactorial antioxidant potential of these newer beta antagonists served to markedly attenuate mitochondrial and cardiac tissue 8-isoprostane levels and the appearance of myocardial scarring [13] .
Intrinsically coupled

Clinical correlates: nonischemic cardiomyocyte necrosis
Acute stressor states A hyperadrenergic response accompanies acute bodily injury, such as acute myocardial infarction (MI), major surgery, including coronary artery bypass surgery, thermal burns, head injury, or subarachnoid hemorrhage, and musculoskeletal trauma. Sepsis and diabetic ketoacidosis are systemic inflammatory illnesses accompanied by a hyperadrenergic state.
Nonischemic myocardial necrosis secondary to catecholamine-induced cell death can lead to elevations in serum troponins. These elevations, however, are modest in comparison to the segmental loss of myocardium with an acute reduction in coronary blood flow and MI. Elevated troponins have been reported in acute stressor states that include sepsis, gastrointestinal bleeding, pulmonary embolus, and subarachnoid hemorrhage [27, 35, 53, 86] . Nonischemic necrosis is a risk factor for multiorgan failure and mortality associated with ventricular dysfunction [2, 91] .
Chronic stressor states
Cardiomyocyte necrosis with elevations in serum troponins indicative of cardiomyocyte necrosis but not due to MI or related to renal failure is found in patients hospitalized with CHF and is associated with increased in-hospital and overall cardiac mortality [29, 32, 33, 50, 52, 55, 62, 68, 78, 92] . The consistent association between troponin elevation and poor outcomes is found in hospitalized and ambulatory patients with HF. A concentration-dependent relationship exists between the magnitude of troponin elevation and adverse outcomes. Consequently, there is the need for serial troponin measurements to assess changing levels of risk. Increased frequency and magnitude of troponin "leak" results in worsened outcomes and transition from compensated to decompensated HF [43] .
Summary and conclusions
Cardiomyocyte survival must be sustained if the efficiency of this muscular pump is to be preserved. Mitochondria play a central role in nonischemic cardiomyocyte necrosis in a pathophysiological scenario, which is common to both acute and chronic stressor states. A mitochondriocentric signaltransducer-effector pathway leads to necrosis. Its major components include the following: catecholamine or PTHmediated intracytosolic and intramitochondrial Ca 2+ overloading; and the induction of oxidative stress by these organelles; and the subsequent opening of their inner mPTP with ensuing osmotic swelling, loss of ATP synthesis, organellar degeneration, and a hyperpermeable sarcoplasmic membrane with spillage of cell contents that includes troponins. The necrotic loss of cells leads to a subsequent wound healing response with invading inflammatory cells and myofibroblasts that eventuates in a replacement fibrosis. Necrosis contrasts to apoptosis, which leaves neither a morphological footprint of fibrosis nor a biochemical trail with elevated troponins. The scattered foci of myocardial scarring found in the explanted failing human heart and the presence of increased serum troponins at the time of hospitalization for episodes of decompensated CHF underscores the importance of cardiomyocyte necrosis and that is ongoing.
Strategic interruption of this pathway by pharmaceuticals and/or nutriceuticals offers a mitochondria-targeted approach toward salvaging cardiomyocytes from necrotic cell death. Experimental evidence gathered to date holds promise for the potential efficacy of such cardioprotective strategies. 
